Products - Pancreatic cancer | Topic | NICE

Showing 4 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
2 February 2026
Expected publication date:
25 March 2026
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2027
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC